The company said that there is increasing evidence that the manganese content in soy milk is linked to neurotoxicity in infants. The current established theory is that newborn infants do not have the ability to metabolize manganese as adults do, and nonmetabolized manganese remains in brain tissue for many years. According to the standards announced by the US Food and Drug Administration, infants can absorb 0.005 mg of manganese per day and adults can absorb 1.2 mg, which is equivalent to more than 200 times that of infants. Some modern medical studies even believe that manganese is a metal that is harmful to nerves. Parkinson's disease is the result of accumulation of large amounts of manganese in the basal ganglia of the brain.
Lumen also said that in the United States and other countries, there have been many researches in the United States and other countries against soy products. 99% of them lack scientific basis, but the negative impact of manganese content in soymilk on the health of infants should be worth 1%. The research that was valued, according to which the company decided to add the “baby not suitable†label to its soymilk products.
But more research shows that soy products are beneficial to human health. Many confirmed studies have shown that phytochemicals in soybeans have an inhibitory effect on many human diseases.
U.S. main soy product manufacturer Lumen Foods Co., Ltd. announced a few days ago that some studies found that the content of manganese in soymilk is 50 times higher than breast milk. Although manganese is needed by the body, excessive absorption may affect the brain development of infants under 6 months of age.